Fortress Biotech Sells PRV for $205M After ZYCUBO Approval
Cyprium Therapeutics (Fortress Biotech subsidiary) just signed a deal to sell its Rare Pediatric Disease Priority Review Voucher for $205M after FDA approval of ZYCUBO for Menkes disease.
/ 3 items
#FBIO↓
FDA Approves First Treatment for Rare Menkes Disease
ZYCUBO becomes the first FDA-approved treatment for Menkes disease, a rare genetic disorder affecting copper transport in children, offering new hope for patients.
Fortress Biotech Stock Plummets After FDA Rejection
FDA rejected Fortress Biotech's Menkes drug, CUTX-101, due to factory issues, but the drug's safety and efficacy data were fine.